Bioanalytical testing involves the quantitative measurement of drugs and their metabolites in biological matrices, such as blood, serum, plasma, or urine. This is a fundamental component of clinical trials, as it provides the data necessary to calculate pharmacokinetic (PK) parameters, such as the maximum concentration (Cmax) and the half-life of the drug. Because biological samples are complex and variable, bioanalytical methods require an even higher level of sensitivity and specificity than standard chemical testing.

The "Gold Standard" for bioanalysis is Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), which allows for the detection of drugs at picogram-per-milliliter levels. Outsourcing bioanalytical work is common due to the extreme cost of these instruments and the specialized training required to operate them. Detailed reports on the service outlook for bioanalytical services in both the preclinical and clinical phases can be found at the Pharmaceutical Analytical Testing Outsourcing Market resource. These labs must adhere strictly to "Good Laboratory Practices" (GLP) to ensure that the data supporting human safety is beyond reproach.

One of the emerging challenges in bioanalysis is the testing of large-molecule biologics, such as monoclonal antibodies. These require Ligand Binding Assays (LBAs), such as ELISA, to measure concentration and immunogenicity. Detecting "Anti-Drug Antibodies" (ADAs) is a critical safety requirement for biologics, as these antibodies can neutralize the drug’s effect or cause severe allergic reactions. Specialized outsourced labs provide the expertise necessary to develop these complex assays and interpret the results within the context of clinical safety.